Skip to content
Evolvere BioSciences logo

Evolvere BioSciences

Evolvere BioSciences is a YC Summer 2024 (S24) company. Based in Oxford, England, United Kingdom. Team of 3.

  • AI-powered Drug Discovery
  • Artificial Intelligence
  • Biotech
  • Therapeutics
  • Biotechnology

About Evolvere BioSciences

GPAgent's own fund-neutral profile, written from public information. Updated Oct 5, 2026.

Summary

Evolvere BioSciences develops antibiotics designed to stay effective as bacteria evolve, using AI models trained on co-evolutionary protein-protein interaction data to anticipate and outpace bacterial mutations. The drugs precisely target pathogenic bacteria while leaving beneficial microbes and human cells unharmed. This approach replaces the recurring cycle of developing new antibiotics in response to resistance, a cycle driven by the failure of conventional drugs that bacteria can eventually overcome.

Go-to-market

The primary customers are healthcare systems, hospitals, and pharmaceutical partners facing drug-resistant bacterial infections, a problem that already outpaces malaria and AIDS in mortality.

From the Y Combinator listing

How Evolvere BioSciences describes itself in Y Combinator's public directory. Original listing (opens in a new tab)

Making Next-Generation Antibiotics that Outpace Bacterial Evolution

🦠🤖 We use our computational models to make next-generation antibiotics that outcompete bacterial evolution and precisely target pathogenic bacteria, without harming good microbes or human cells. ☠️ Current antibiotics stop working because bacteria evolve resistance to them. This makes drug-resistant bacteria a looming global health crisis - already killing more people than malaria and AIDS and it is getting exponentially worse 📈. 🧬 Our approach leverages co-evolutionary protein-protein interaction datasets combined with AI to forecast bacterial mutations and create ‘future-proof’ antibiotics, addressing antibiotic resistance before it develops. This changes the game for how frequently society will need to make new antibiotics and how long our new antibiotics will be able to treat patients 👩‍⚕️. We are a team of biochemists and evolutionary biologists who met at the University of Oxford.

Facts

Industry
Healthcare / Healthcare -> Therapeutics
Location
Oxford, England, United Kingdom
Team size
3
Status
Active
Stage
Early

Founders (3)

Score every batch against your own thesis

GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.

How Accelerator intelligence works